ABSTRACT
INTRODUCTION
Transvaginal ultrasound is often used to manage patients with postmenopausal bleeding. If the sonographic endometrial thickness is ≤ 4 mm, the risk of any endometrial pathology is low, and the patient can be discharged without endometrial sampling [1] [2] [3] . If the endometrial thickness is ≥ 5 mm, the risk of endometrial cancer is higher 1, 3 , and the thicker the endometrium, the higher the risk 1, [4] [5] [6] . The risk also depends on the grayscale ultrasound morphology of the endometrium and its vascularity as assessed with color or power Doppler ultrasound [4] [5] [6] . Because individual risk estimates enable individualized management, our research team published multivariable logistic regression models to calculate the individual risk of endometrial malignancy in women with endometrial thickness ≥ 4.5 mm; five performed particularly well (Table 1) 5 . These models contained information on endometrial thickness, the echogenicity of the endometrium and the morphology and arrangement of the endometrial blood vessels on power Doppler ultrasound. They were developed specifically for patients Table 1 Mathematical formulae for the five multivariable logistic regression models 5 for prediction of endometrial malignancy with postmenopausal bleeding and endometrial thickness ≥ 4.5 mm, no fluid in the uterine cavity and detectable power Doppler signals in the endometrium 5 . The arguments for creating models for this specific subgroup of patients were presented in the original study. Briefly, they were created for women without fluid in the uterine cavity because information on endometrial echogenicity or vascularity adds little to diagnosis when there is fluid in the uterine cavity 7, 8 . Moreover, the color Doppler image of the endometrium differs depending on whether or not there is fluid in the uterine cavity 7 , which means that separate models would need to be developed for women with and those without fluid. The models were created for women with detectable power Doppler signals in the endometrium because we wanted to know what diagnostic information there is in the morphology and arrangement of the endometrial vessels; if no vessels are detected this question cannot be answered.
Without validation, one cannot know if a model performs equally well when applied to patients other than those in the study in which the model was created 9 . The aim of this study was to validate prospectively the diagnostic performance of the five published logistic regression models described in Table 1 when applied to the defined high-risk group of patients for which they were created.
PATIENTS AND METHODS
This was a prospective observational temporal validation study, in which all data were collected prospectively and applied to new patients. The patients were recruited from the postmenopausal bleeding clinic at the Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden. This clinic was run by one of two gynecologists (L.V. or P.S.), both of whom had more than 15 years' experience in gynecological ultrasound at the start of the study. Recruitment was between 1 September 2005 and 1 March 2013. Postmenopause was defined as absence of vaginal bleeding for at least 1 year after the age of 40 years, provided that the amenorrhea could not be explained by medication or disease. Postmenopausal bleeding was defined as any vaginal bleeding in a postmenopausal woman not on hormone replacement therapy, or as unscheduled vaginal bleeding in a postmenopausal woman on hormone replacement therapy. If a patient who was eligible for inclusion consulted our postmenopausal bleeding clinic more than once during the study period, the examination at which endometrial thickness was ≥ 4.5 mm was included (44 patients consulted twice, three patients thrice and one patient four times). If endometrial thickness was ≥ 4.5 mm at more than one examination, the examination with the most complete information was included.
For more than 15 years, patients attending our clinic because of postmenopausal bleeding have been managed in the same standardized manner. First, a standardized history following a study protocol is taken; then, a gynecological examination including a vaginal smear to screen for cervical cancer is carried out; and, finally, a transvaginal ultrasound examination with measurement of endometrial thickness is performed. The endometrial thickness is measured as described previously 10 . If the endometrial thickness is ≤ 4.4 mm, the patient is discharged without endometrial sampling. If the endometrial thickness is ≥ 4.5 mm, or if the endometrium cannot be seen clearly, saline contrast sonohysterography (SCSH) is carried out as described previously 11 . If there are focal lesions on SCSH, the patient is scheduled for operative hysteroscopy, with surgical removal of the focal lesions under direct visual control. If there are no focal lesions, an endometrial sample is taken using the Endorette™ outpatient endometrial sampling device (Medscand ® , Cooper Surgical, Trumbull, USA). If Endorette sampling fails, the patient is booked for dilatation and curettage (D&C). If SCSH fails, diagnostic hysteroscopy is scheduled and followed by operative hysteroscopy if focal lesions are detected at hysteroscopy, or by D&C if no focal lesions are detected. Patients with spontaneous fluid in the uterine cavity are managed in the same manner as those undergoing SCSH. The definition of focal lesion is the same as that used in the International Endometrial Tumor Analysis consensus statement, i.e. anything that protrudes above the baseline endometrial surface into the uterine cavity is classified as a focal lesion 10 . Patients were eligible for inclusion in our study if their sonographic endometrial thickness was ≥ 4.5 mm and if there was no spontaneous fluid in the uterine cavity. Examinations were performed with the woman in the lithotomy position with an empty bladder, using a Sequoia 512 ultrasound system (Siemens Medical Solutions Inc., Ultrasound Division, Mountain View, CA, USA) equipped with a 4-8-MHz transvaginal transducer. First, conventional grayscale ultrasound examination of the uterus and endometrium was performed, and then power Doppler ultrasound examination of the endometrium was carried out using predetermined, standardized settings, i.e. the same settings as in the original study (frequency, 6 MHz; power Doppler gain, 50; dynamic range, 10 dB; edge, 1; persistence, 2; color map, 1; gate, 2; filter, 3). Images and videoclips were saved in our electronic image management system (Syngo Dynamics, Siemens Healthcare, Erlangen, Germany). Information on all the variables included in the models to be validated was collected prospectively, i.e. endometrial thickness, endometrial grayscale ultrasound morphology and endometrial vessel morphology and arrangement on power Doppler ultrasound examination. The results were entered into a dedicated research protocol immediately after the ultrasound examination. The same ultrasound terminology and definitions as in our original study 5 were used.
The gold standard was the histological diagnosis of the endometrium obtained by the Endorette device, D&C, hysteroscopic resection of focal lesions, hysteroscopic resection of the endometrium or hysterectomy. If only one of several samples from the same patient indicated malignancy, the malignant diagnosis was accepted as the final one. Endometrial hyperplasia with atypia was regarded as a benign diagnosis, because this was the classification used in our original study 5 . The models were validated with regard to discrimination (benign vs malignant) and calibration. Each of the five logistic regression models 5 was applied to calculate the individual risk of endometrial malignancy. The discriminative ability of the models and of sonographic endometrial thickness alone was expressed as the area under the receiver-operating characteristics curve (AUC) and as the sensitivity, specificity and positive and negative likelihood ratios when using the cut-offs to predict malignancy suggested in the original study 5 . The statistical significance of differences in AUC between methods was calculated using the method described by DeLong and coworkers 12 . Calibration of the predicted probabilities of malignancy was performed by creating calibration plots. These describe the relation between the predicted and observed probabilities of malignancy within the chosen decile of calculated risk, and the mean absolute percentage error provides a measure of bias 13 . The statistical software programs used were the Statistical Package for the Social Sciences software (PASW version 18.0, SPSS, IBM Corp., New York, NY, USA), the Stata Statistical Software (Release 13, StataCorp LP, College Station, TX, USA) and MedCalc statistical software (MedCalc software bvba, Ostend, Belgium) provided on the website http://www.medcalc.org.
The ethics committee of Lund University approved the study protocol and informed consent was obtained from all participants after the nature of the procedures had been explained fully to them.
RESULTS
In total, 1012 consecutive patients with postmenopausal bleeding were examined in our postmenopausal bleeding clinic during the study period. Of these, 525 patients were not eligible for inclusion. Of the 487 patients eligible for inclusion, 11 were not examined according to the study protocol. Of the 476 patients examined according to the protocol, 50 were excluded because there were no detectable power Doppler signals in the endometrium and 47 were excluded because at 6-month follow-up there was still no histological diagnosis of the endometrium (27 patients declined surgery after failed outpatient endometrial sampling, six patients had cervical cancer or other cancer and 14 patients, i.e. 3%, were lost to follow-up). In all, 379 patients with postmenopausal bleeding and endometrium ≥ 4.5 mm fulfilled our inclusion criteria (which were the same as in the study in which the models were created) and were used in our statistical calculations. One hundred and forty-five of the 379 patients were also included in another study with a different aim 6 . Patient recruitment is described in Figure 1 . Demographic background data and ultrasound findings for the patients included are presented in Table 2 . The patients' age ranged between 43 and 93 (median, 66) years; 100 (27%) patients used hormone replacement therapy (including low-dose oral estrogens and local estrogens) and 14 (4%) patients used Tamoxifen. 
Figure 1
Flowchart showing recruitment of patients into the study. *Absence of endometrial histology is explained by patients declining surgery after failed outpatient endometrial sampling because of old age (n = 11) or severe somatic diseases (n = 16), by the diagnosis being cervical cancer (n = 2) or vaginal cancer (n = 4) or by loss to follow-up (n = 14). ET, endometrial thickness. Ninety-three (25%) patients had malignant endometrium. The specific histological diagnoses and the grade and stage of endometrial cancer are shown in Table 3 . Eighty-nine of the 93 patients with a final diagnosis of malignant endometrium and 12 of the 14 patients with atypical endometrial hyperplasia in the primary endometrial sample underwent hysterectomy.
The discriminative performance of endometrial thickness alone and of each of the models is shown in Table 4 . The models performed well, their AUCs varying between 0.86 and 0.90. Using the previously suggested optimal cut-off values to predict malignancy 5 , the sensitivity with regard to malignancy of the five models ranged from 59% to 86% and the specificity from 76% to 93%. The model including endometrial thickness, endometrial heterogeneous echogenicity and areas of densely packed vessels on power Doppler ultrasound (Model 4) had particularly good diagnostic performance (AUC, 0.90; sensitivity, 81%; specificity, 84%, positive likelihood ratio 5.05 and negative likelihood ratio 0.22 when using the previously suggested cut-off of 0.28).
The discriminative performance of the five models when applied to the 340 patients with information on all the variables needed for all five models (255 benign and 85 malignant endometria) is shown in Figure 2 and in Table  S1 . All models performed better than did endometrial thickness alone and Model 4 was superior to Models 2, 3 and 5.
When the 14 cases of hyperplasia with atypia were included in the malignant group, the discriminative performance deteriorated; the sensitivity in particular decreased. The AUCs for the five models varied between 0.80 and 0.85, the sensitivity between 56% and 78% and the specificity between 72% and 89% (Table S2 and Figure S1 ). Calibration plots for each of the five models are shown in Figure 3 . The models were well calibrated.
DISCUSSION
We have shown that, on prospective temporal validation, five published multivariable logistic regression models 5 designed to estimate the risk of endometrial malignancy in a defined high-risk group of patients with postmenopausal bleeding performed well when applied to the patient group for which they were designed. The model that included information on endometrial thickness, endometrial heterogeneous echogenicity and areas with densely packed vessels (Model 4) performed particularly well. Using Model 4, a calculated risk of malignancy above 0.28 (the previously suggested cut-off) increased 
Figure 2
Receiver-operating characteristics (ROC) curves for five logistic regression models (Table 1) to calculate risk of endometrial malignancy in patients with postmenopausal bleeding, sonographic endometrial thickness ≥ 4.5 mm, no fluid in the uterine cavity and detectable color Doppler signals in the endometrium. Models were applied to 340 patients (255 with benign and 85 with malignant endometria) with information available for all variables included in all five models. Sensitivity, specificity and positive and negative likelihood ratios when applying the cut-off values suggested in the original publication 5 are presented in Table S1 . The area under the ROC curve (AUC) for endometrial thickness (ET, ; AUC = 0.79) was statistically significantly smaller than that of Model 1 ( ; AUC = 0.88; P = 0.0001), Model 2 ( ; AUC = 0.86; P = 0.0003), Model 3 ( ; AUC = 0.86; P = 0.0035), Model 4 ( ; AUC = 0.90; P = <0.0001) and Model 5 ( ; AUC = 0.87; P = 0.0228). The AUC of Model 4 was statistically significantly larger than that of Model 2 (P = 0.0312), Model 3 (P = 0.0018) and Model 5 (P = 0.0027) but not statistically significantly larger than that of Model 1 (P = 0.0546).
, Reference line.
the odds of malignancy five-fold, whereas a risk of 0.28 or less decreased the odds of malignancy five-fold. All models were well calibrated.
There have been no previous publications describing prospective validation of mathematical models designed to predict endometrial malignancy in women with postmenopausal bleeding, despite many such models having been published [4] [5] [6] [14] [15] [16] . A limitation of our study is that the ultrasound examinations were carried out by highly experienced ultrasound examiners. Therefore, these results might not be applicable to less experienced examiners.
The five models showed only a small decline in discriminative performance compared with that in the original study 5 : AUC for Model 1 was 0.88 in the current study vs 0.89 in the original study; AUC for Model 2 was 0.86 vs 0.86; AUC for Model 3 was 0.86 vs 0.85; AUC for Model 4 was 0.90 vs 0.92; AUC for Model 5 was 0.87 vs 0.89. Moreover, all the models retained their place in the hierarchical order from best to poorest, i.e. Model 4 was the best model in both studies, Model 1 was the second best in both studies, Model 5 was the third best in both studies. These results are reassuring and indicate that our models are robust.
While Model 4 manifested the best discriminative performance, Model 1, which also had good discriminative ability, may be more attractive to use in clinical practice, because it includes no Doppler information. Assessing endometrial vessels using Doppler ultrasound requires an ultrasound system with high Doppler sensitivity and a highly experienced ultrasound examiner. However, Model 5, which includes no information on endometrial thickness, is likely to be the most clinically attractive model to use. It gives four risk estimates. Patients can be classified easily, without entering the variables into the model, as: having probably benign endometrium (homogeneous endometrium and no area of densely packed vessels), possibly malignant endometrium (homogeneous endometrium with area of densely packed vessels), probably malignant endometrium (heterogeneous endometrium but no area of densely packed vessels) or certainly malignant endometrium (heterogeneous endometrium with area with densely packed vessels). Model 5 manifested Model 5 can be used to classify patients into four groups: probably benign endometrium (homogeneous endometrium, no area of densely packed vessels); possibly malignant endometrium (homogeneous endometrium, area of densely packed vessels); probably malignant endometrium (heterogeneous endometrium, no area of densely packed vessels); certainly malignant endometrium (heterogeneous endometrium, area of densely packed vessels).
almost perfect agreement between the calculated risk of malignancy and the true prevalence of malignancy.
Our models were not created to be used in all patients with postmenopausal bleeding but can be used to individualize patient management. All the women in our study (postmenopausal bleeding and endometrium ≥ 4.5 mm) were candidates for further investigations to exclude endometrial cancer. Our models were created to quantify the risk of endometrial malignancy in this high-risk group of women in order to reclassify them as having a low or relatively low risk, a moderately high risk or very high risk of endometrial cancer. Both SCSH and outpatient endometrial sampling often fail in postmenopausal patients 8, 11, [17] [18] [19] [20] . This is when our models are particularly useful, because women declining outpatient procedures or in whom they fail need to undergo investigations requiring anesthesia or analgesia, and many countries have waiting lists for such medical procedures. Women classified as having a very high risk of endometrial cancer by our methods can be given priority on a waiting list for a diagnostic procedure requiring analgesia or anesthesia, while those classified as having a relatively low risk can wait longer. In some patients with low cancer risk but high operative risk it may be justified to refrain from further investigations altogether. Moreover, if the ultrasound findings indicate a high risk of malignancy (Model 5, Figure 3 ) it is reasonable to proceed directly to outpatient endometrial sampling and not perform SCSH, because there is no need to clarify the situation, and there may be a small risk of spreading malignant cells into the peritoneal cavity 21 . In addition, in such cases, one should not accept a diagnosis of 'insufficient material' or a benign histological diagnosis in a sample obtained by blind endometrial sampling. Instead, one should proceed with hysteroscopy. Outpatient endometrial sampling yields insufficient material for diagnosis in 16-68% of patients with postmenopausal bleeding [18] [19] [20] 22, 23 , and the histological diagnosis may be false negative with regard to malignancy in up to 27% of all blind sampling procedures 24, 25 . Our models were constructed to predict only invasive malignancy, not endometrial hyperplasia with atypia 5 . Because of the relatively high prevalence (6-63%) of coexistence of endometrial hyperplasia with atypia and early endometrial cancer 26 , it is recommended that patients with endometrial hyperplasia with atypia undergo hysterectomy with bilateral salpingo-oophorectomy 26, 27 . Consequently, it would be clinically valuable to have a model capable of predicting not only invasive endometrial malignancy but also endometrial hyperplasia with atypia. Our models were not constructed to do so, and therefore they performed less well when hyperplasia with atypia was included in the malignant group (Table S2 ; Figure S1 ).
To summarize, on prospective temporal validation, the discriminative ability of five published logistic regression models to calculate the risk of endometrial malignancy in a defined high-risk group of patients with postmenopausal bleeding was good and the models were well calibrated. Model 5 is particularly attractive, because it can classify patients into four risk groups without requiring the variables to be entered into a mathematical model. The models make it possible to reclassify high-risk patients as having a low or relatively low risk, a moderately high risk or a very high risk of endometrial cancer, and so can be used for individualized patient management. These models should now undergo external validation in centers unrelated to ours. Their performance in the hands of less experienced examiners also needs to be estimated.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Figure S1 Receiver-operating characteristics (ROC) curves for five logistic regression models to calculate risk of endometrial malignancy, when cases of endometrial hyperplasia with atypia were classified as malignant, in patients with postmenopausal bleeding, sonographic endometrial thickness ≥ 4.5 mm, no fluid in the uterine cavity and detectable color Doppler signals in the endometrium. The models were applied to 340 patients (241 benign endometria and 99 malignant endometria) with information available for all variables included in all five models.
Table S1
Results of temporal validation of five multivariable logistic regression models to predict endometrial malignancy when applied to 340 patients with information available for all variables included in all five models (255 benign endometria and 85 malignant endometria) Table S2 Results of temporal validation of five multivariable logistic regression models to predict endometrial malignancy when applied to 340 patients with information available for all variables included in all five models, when endometrial hyperplasia with atypia (n = 14) is classified as malignant (241 benign endometria and 99 malignant endometria)
